Natixis Advisors LLC Cuts Stock Holdings in Pfizer Inc. (NYSE:PFE)

Natixis Advisors LLC lowered its position in Pfizer Inc. (NYSE:PFE) by 7.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,223,808 shares of the biopharmaceutical company’s stock after selling 174,092 shares during the quarter. Natixis Advisors LLC’s holdings in Pfizer were worth $58,998,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Swedbank AB grew its holdings in Pfizer by 0.7% in the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after acquiring an additional 37,636 shares during the last quarter. United Bank grew its holdings in Pfizer by 3.7% in the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock worth $1,030,000 after acquiring an additional 1,277 shares during the last quarter. GSA Capital Partners LLP grew its holdings in Pfizer by 87.6% in the 3rd quarter. GSA Capital Partners LLP now owns 32,786 shares of the biopharmaceutical company’s stock worth $949,000 after acquiring an additional 15,310 shares during the last quarter. Curi RMB Capital LLC grew its holdings in Pfizer by 4.7% in the 3rd quarter. Curi RMB Capital LLC now owns 55,770 shares of the biopharmaceutical company’s stock worth $1,614,000 after acquiring an additional 2,487 shares during the last quarter. Finally, CIBC Asset Management Inc grew its holdings in Pfizer by 6.2% in the 3rd quarter. CIBC Asset Management Inc now owns 1,065,338 shares of the biopharmaceutical company’s stock worth $30,831,000 after acquiring an additional 61,988 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Up 0.5 %

Shares of NYSE:PFE opened at $25.74 on Friday. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The firm has a market capitalization of $145.85 billion, a PE ratio of 18.25, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business has a 50 day simple moving average of $26.24 and a two-hundred day simple moving average of $27.13.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same period last year, the business posted $0.10 earnings per share. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on PFE. Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Bank of America reaffirmed a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Citigroup cut their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.